Minhong Tang

An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Yvette Drew, Maja J.A. de Jonge, Sook Hee Hong et al. · Gynecologic Oncology · 2018 · 130 citations

Gbrca M, Medicine, Gynecology +6

Structural Insight into How <i>Streptomyces coelicolor</i> Maltosyl Transferase GlgE Binds α-Maltose 1-Phosphate and Forms a Maltosyl-enzyme Intermediate

Karl Syson, Clare E. M. Stevenson, Abdul Rashid et al. · Biochemistry · 2014 · 35 citations · Full text

M. Tuberculosis Enzyme, Glycobiology, Molecular Biology +16

MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

Minhong Tang, Shane O’Grady, John Crown et al. · Breast Cancer Research and Treatment · 2022 · 33 citations · Full text

New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators

Minhong Tang, Jianghui Meng, Jiafu Wang · International Journal of Molecular Sciences · 2019 · 27 citations · Full text

Abstract PD5-04: An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Updated results in patients with germline <i>BRCA</i>-mutated (g<i>BRCA</i>m) metastatic breast cancer (MBC)

S. M. Domchek, Sophie Postel‐Vinay, S-A. Im et al. · Cancer Research · 2019 · 17 citations

Median Dor, Breast Oncology, Immunology +18